Quadruplet therapy, with the addition of daratumumab (D), a monoclonal antibody targeting CD38, has shown promising results in different clinical trials [42,43,44] and is currently used by some centers in patients with high-risk MM [45]. Here, CD38 is linked to Miyoshi myopathy.